DJIA 17,757.91 138.40 0.79%
NASDAQ 5,013.12 26.26 0.53%
S&P 500 2,077.42 14.31 0.69%
market minute promo

Incyte Corp (NASDAQ: INCY)

104.45 0.24 (0.23%)

REAL-TIME: Last trade at

Extended Hours: $104.01 -$0.44 (-0.42%)
Quote as of (NASDAQ)

company name or ticker

Recent Quotes

INCY $104.45 0.23%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $105.15
Previous Close $104.21
Daily Range $102.42 - $105.86
52-Week Range $43.86 - $113.55
Market Cap $18.7B
P/E Ratio -548.47
Dividend (Yield) $0.00 (0.0%)
Volume 849,445
Average Daily Volume 919,604
Current FY EPS -$0.30




Drug Makers

Incyte Corp (INCY) Description

The Company is a drug discovery and development company focused on developing proprietary small molecule drugs to treat serious unmet medical needs. Website:

News & Commentary

Cancer Drugs: 2 Stocks to Watch

AstraZeneca and Agenus Inc. are paving the way for a new generation of breakthrough cancer drugs that boost the immune system's ability to detect and eradicate malignancies. Here's what investors need to know about these two biopharmas going forward.

Immunovaccine Collaborates With Incyte to Evaluate Novel Immunotherapy Combination for Patients With

Immunovaccine Collaborates With Incyte to Evaluate Novel Immunotherapy Combination for Patients With Platinum-Sensitive Ovarian Cancer

Agenus Gets Billion-Dollar Valuation From Analyst Based on Cancer Drug That Doesn't Exist

The Best Pairs Trade In The Market: Buy Geron And Short Incyte

High Time To Go Short Incyte Pharmaceuticals

JMP Sees A 'Negative Market Tone' In Biotechnology

Lilly and Incyte unveil detailed data on two pivotal studies of baricitinib in rheumatoid arthritis

Agenus Gains after Merck Extends Immuno-Oncology Ties - Analyst Blog

What Caused Eli Lilly and Co. Shares to Vault Higher in May?

Pharmaceutical giant Eli Lilly made double-digit percentage gains in May after two end-of-the month announcements. Find out what these announcements were about, why shareholders are so excited, and whether this run higher can last.

Why Shares in Advaxis, Inc. Are Surging Higher

Advaxis, Inc. is heading higher on news that it will launch another clinical trial for ADXS-HPV.

See More INCY News...

INCY's Top Competitors

INCY $104.45 (0.23%)
Current stock: INCY
AMGN $154.99 (0.96%)
Current stock: AMGN
GILD $116.01 (-0.91%)
Current stock: GILD
BIIB $405.41 (0.36%)
Current stock: BIIB